Delivery Order SPE2DB22D1017-SPE2DB26FYPCX
- Not listed
- The Defense Logistics Agency awarded a $9,266.70 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Tavalisse 100 mg tablets (60-count units) on April 24, 2025, with an ultimate completion date of May 15, 2025. This non-competitive delivery order is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $9,266.70 to AmerisourceBergen Drug Corp for the supply of Tavalisse 100 mg tablets (60-count) under a firm fixed-price contract type. The contract, which was competitively awarded with no set-aside designation, is scheduled for completion by August 25, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Tavalisse 100 mg tablets (60-count units) with a contract ceiling value of $9,266.70. This firm fixed-price delivery order, which is not set-aside and competitively awarded, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $9,296.97 to AmerisourceBergen Drug Corp for Tavalisse 150 mg tablets (60-count) on September 3, 2025, with completion expected by September 24, 2025. This firm fixed price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Tavalisse is a prescription medication used to treat immune thrombocytopenia, a bleeding disorder affecting...
- The Defense Logistics Agency awarded a $9,266.70 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 10, 2025, for the supply of Tavalisse 100 mg tablets (60-count units). This is a non-set-aside contract with a completion date of July 31, 2025, and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,266.70 to AmerisourceBergen Drug Corp for the supply of Tavalisse 100 mg tablets (60 count) under a firm fixed-price contract. The order was competitively awarded without a set-aside designation and carries an ultimate completion date of October 3, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, served as the prime contractor, with performance of the work taking place at its corporate office location...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Tavalisse 100 mg tablets (60-count units) with a ceiling value of $18,533.40. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 10, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation, indicating it was competed among all eligible...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Tavalisse 100 mg tablets (60-count units) under a firm fixed-price contract valued at $9,266.70. This is a non-set-aside, competitively awarded delivery order with an ultimate completion date of October 16, 2025. AmerisourceBergen will perform this work from its corporate office location in Conshohocken, Pennsylvania, where the company is headquartered. This delivery...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Tavalisse 150 mg tablets (60-count) with a contract ceiling value of $18,593.94. This competitively awarded, non-set-aside delivery order utilizes firm fixed price pricing and is scheduled for completion by October 3, 2025. The order will be fulfilled from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Tavalisse 100 mg tablets (60-count units) with a ceiling value of $9,266.70. This firm fixed-price delivery order, due for completion by September 23, 2025, represents a non-set-aside competitive award to support federal medical procurement needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB26FYPCXDelivery Order
The Defense Logistics Agency (DLA) awarded a $9,296.97 delivery order to AmerisourceBergen Drug Corp for the supply of Tavalisse 150 mg tablets (60-count packages) on October 16, 2025, with an ultimate completion date of November 6, 2025. This firm fixed price, competitively awarded contract contains no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion pharmaceutical support vehicle running through December 2026 that enables the company to supply an extensive range of pharmaceutical products and medical supplies globally to military healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical federal medical procurement vendor specializing in brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. The company's extensive portfolio of competitively awarded federal contracts demonstrates its capability to fulfill diverse medical supply needs for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. Tavalisse (fostamatinib) is an oral immunosuppressive agent used in the treatment of immune thrombocytopenia, supporting the DLA's mission to provision pharmaceutical products essential for military personnel and veteran healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.3k | 10/16/25 |